VIVUS Settles with Dr. Reddy's Laboratories on Qsymia Patent Litigation

VIVUS (NASDAQ:VVUS) announced it entered into a settlement agreement with Dr. Reddy’s Laboratories related to the patent litigation of Qsymia capsules CIV.
As quoted in the press release:

The litigation, which has been pending in the U.S. District Court for the District of New Jersey since 2015, resulted from the submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration seeking approval to market generic versions of Qsymia. The settlement agreement permits Dr. Reddy’s to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, VIVUS will receive a royalty on sales of the generic version of Qsymia.
This settlement with Dr. Reddy’s concludes all patent litigation brought by VIVUS against generic pharmaceutical companies that have filed ANDAs seeking approval to market generic versions of Qsymia®. As required by law, VIVUS and Dr. Reddy’s will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

Click here to read the full press release.

Source: www.marketwired.com